Skip to main content
EJNMMI Research

Table 5 177Lu-PSMA studies reporting hematologic adverse events

From: Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Study

Ref

n

Cycles

Ligand

Activity (GBq/cycle, range)

Anemia grade 1/2

Leukopenia/*neutropenia grade 1/2

Thrombocytopenia grade 1/2

Anemia grade 3/4

Leukopenia/*neutropenia grade 3/4

Thrombocytopenia grade 3/4

Ahmadzadehfar et al. 2015

[10]

10

10

PSMA-617

5.6

1 (10%)

3 (30%)

2 (20%)

1 (10%)

0

0

Ahmadzadehfar et al. 2016

[11]

24

46

PSMA-617

6 (4.1–7.1)

7 (29%)

5 (21%)

4 (17%)

2 (8%)

0

0

Barber et al. 2019

[35]

84/83

n/a

PSMA-617,-I&T

6.3 (5.7–6.8)

81(96%)/73(88%)

22(26%)/23(28%)

21(25%)/27(33%)

1(1%)/7(8%)

0/2(2%)

1(1%)/3(4%)

Baum et al. 2016

[12]

56

125

PSMA-I&T

5.8

n/a

n/a

n/a

0

0

0

Bräuer et al. 2017

[13]

59

159

PSMA-617

6.1 (5.9–6.3)

n/a

n/a

n/a

11 (19%)

2 (4%)

2 (4%)

Derlin et al. 2020

[34]

31/40

n/a

PSMA-617

6.0–7.4

9 (29%)/6 (15%)

5 (16%)/4(10%)

3(10%)/4(10%)

0

0

0

Emmett et al. 2018

[36]

14

n/a

PSMA-617

6.0–8.0

2 (14%)

n/a

1/14 (7%)

0

0

0

Fendler et al. 2016

[14]

30

30

PSMA-617

3.7 or 6

n/a

n/a

n/a

1 (3%)

3 (3%)

0

Heck et al. 2016

[15]

22

43

PSMA-I&T

3.7–7.4

3 (14%)

1*(5%)

5 (23%)

0

0

0

Heck et al. 2018

[9]

100

317

PSMA-I&T

7.4

n/a

n/a

n/a

9 (9%)

6* (6%)

4 (4%)

Hofman et al. 2018

[8]

30

86

PSMA-617

7.5

4 (13%)

11* (37%)

8 (27%)

4 (13%)

11* (37%)

4 (13%)

Hofman et al. 2021

[44]

98

n/a

PSMA-617

6.0–8.5

19 (19%)

10 (10%)

18 (18%)

8 (8%)

1 (1%)

11 (11%)

Kratochwil et al. 2016

[16]

30

70

PSMA-617

3.7–6.0

9 (30%)

8 (27%)

4 (18%)

1 (5%)

0

1 (5%)

Paganelli et al. 2020

[37]

43

n/a

PSMA-617

3.7–5.5

28 (65%)

3*(6.9%)

3(6.9%)

2 (4.8%)

0

0

Rahbar et al. 2016

[18]

74

74

PSMA-617

6.0

26 (35%)

9 (12%)

16 (22%)

1(1%)

0

1 (1%)

Rahbar et al. 2016

[38]

28

50

PSMA-617

5.9

3 (14%)

3 (14%)

5 (23%)

0

0

0

Rathke et al. 2018

[39]

40

120

PSMA-617

4–9.3

0

8 (20%)

2 (5%)

0

1 (3%)

2 (5%)

Scarpa et al. 2017

[40]

10

29

PSMA-617

6 (5.4–6.5)

n/a

n/a

n/a

0

0

0

Seifert et al. 2020

[41]

37/41

n/a

PSMA-617

6.0/7.5

(35%)/(27%)

(49%)/(49%)

(41%)/(34%)

(22%)/(24%)

(8%)/(2%)

(8%)/(2%)

Violet et al. 2019

[42]

50

n/a

PSMA-617

7.5

9 (18%)

12* (24%)

14 (28%)

5 (10%)

3* (6%)

5 (10%)

Yadav et al. 2016

[43]

31

65

PSMA-617

1.1–7.4

9 (31%)

n/a

1 (3%)

1 (3%)

n/a

0

Yadav et al. 2020

[48]

90

281

PSMA-617

1.1–7.8

72 (78%)

10 (11%)

14 (16%)

2 (2%)

1 (1%)

1 (1%)

  1. n/a Not available
Back to article page